Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Addex Therapeutics reported Q1 2026 results and a corporate update. The company said its spin-out Neurosterix is on track to complete Phase 1 in July for NTX-253, an M4 positive allosteric modulator for schizophrenia. Q1 2026 net loss was CHF 1.712m vs CHF 1.473m in Q1 2025; cash fell to CHF 0.935m from CHF 2.825m.
How this was made
The 30-second read
Why it matters
Q1 2026 financials show continued net losses and a sharp cash decline, while management reiterates a concrete clinical milestone for NTX-253 in July. Traders may reprice the probability/timing of Phase 1 completion and reassess financing risk based on the reduced cash balance.
Market read
Fresh quarterly cash/runway data plus a specific July clinical milestone can drive near-term sentiment and positioning into the upcoming data window.
What to watch
Cash at CHF 0.9m and equity decline could make the market focus more on financing plans than on the NTX-253 timeline; the release also notes R&D near nil due to zero-cost services from Neurosterix, which may mask underlying spend needs.
Background
Addex Therapeutics is a clinical-stage neuro-focused biopharma; it has a spin-out, Neurosterix, advancing NTX-253 (M4 positive allosteric modulator) in Phase 1.
Ticker impact
Addex reported Q1 2026 results and said Neurosterix is on track to complete Phase 1 for NTX-253 in July.
Likely modest positive bias on clinical timeline confidence, offset by dilution/funding overhang from low cash.
The article provides fresh quarterly financial datapoints (cash, net loss) plus a specific development-timing statement (Phase 1 completion in July). No valuation or guidance is given, so impact is likely incremental rather than a major repricing driver.
Market effects
Highlights typical clinical-stage biotech dynamics: low R&D spend tied to spin-out services and runway pressure from cash burn.
Could influence sentiment for Swiss-listed small-cap biotechs ahead of upcoming clinical readouts.
Limited broader read-across; mainly company-specific for neurological small-molecule allosteric modulators.
Counterpoint
The July Phase 1 completion timing may not translate into near-term value if results are delayed or if funding needs force dilution before data.
Key entities
- companyAddex Therapeutics
Reported Q1 2026 financial results and provided a corporate update including NTX-253 Phase 1 timing.
- spin_outNeurosterix
Spin-out progressing NTX-253 Phase 1; Addex says it is on track to complete the study in July.
- clinical_programNTX-253
M4 positive allosteric modulator candidate for schizophrenia; Phase 1 completion targeted for July.
